Gene and cell therapies hold the potential to provide a cure for Central Nervous System (CNS) disorders. To fulfill the unmet need in the CNS disorders market, at present, several key players such as Novartis, Hope Biosciences, Roche, Brainstorm Cell Therapeutics, Helixmith, Libella Gene Therapeutics, Axovant, Voyager Therapeutics, etc. are expanding their pipelines to incorporate Gene and cell therapy (GCT) to treat a range of CNS disorders.
However, the lack of long-term efficacy data, cost-effectiveness, regulatory challenges, and the absence of standardized guidelines hampers the market growth.
For more details, visit: Gene And Cell Therapies In CNS Disorders Market